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The Role of Kinase Fusion DNAJB1-PRKACA in Fibrolamellar Hepatocellular Carcinoma 
 
Cassandra A. Kersten1, Bing Shui1, Robert J. Plummer1, Lixia Guo2, Angela Gregor1, Kenneth 
C. Uy1, Yanan Yang1, 2, Michael S. Torbenson3, Ying Peng1, and Yi Guo1, 4 
 
1Department of Biochemistry and Molecular Biology,  
2Division of Pulmonary and Critical Care Medicine,  
3Division of Laboratory Medicine and Pathology,  
4Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA 	
Background: Kinase fusion has been detected in a variety of cancer types. Approximately 3% of 
cancers are associated with different kinase fusions, including fibrolamellar hepatocellular 
carcinoma (FLC). FLC is a rare type of liver cancer that predominantly occurs in teenage 
population without any previous liver disease history. It is aggressive and currently surgical 
resection remains the only effective therapeutics. DNAJB1-PRKACA fusion is detected in at 
least 80% of FLC cases and is considered a potential oncogenic factor. However, the causality 
between DNAJB1-PRKACA fusion and FLC is not yet established.  
 
Methods: This study aims at investigating the function of DNAJB1-PRKACA fusion in FLC 
oncogenesis using Drosophila and murine in vivo models. We used the Gal4/UAS system to 
overexpress human DNAJB1-PRKACA fusion gene in Drosophila eyes and used genetic and 
pharmaceutical inhibition of PKA activity to rescue the eye phenotype. We also used 
CRISPR/Cas9 genome engineering to recreate the murine chromosomal deletion equivalent to 
that found in FLC patients. gRNAs were designed to target murine DNAJB1 and PRKACA 
introns and tested for their editing efficiency. Co-transfection of a pair of effective gRNAs 
successfully generated a 360kb chromosomal deletion on chromosome 8 in murine hepatocytes. 
Multiple single cell clones were isolated, first characterized for their in vitro proliferation 
properties, and further inoculated subcutaneously in vivo to monitor their oncogenicity.  
 
Results: Human DNAJB1-PRKACA fusion gene, when expressed in Drosophila eye progenitor 
cells, induced proliferation and differentiation phenotypes, including decreased eye size and 
abnormal eye shape. Both genetic and pharmaceutical inhibition of PKA activity rescued the fly 
eye phenotype. Murine hepatocyte cell lines carrying endogenous DNAJB1-PRKACA fusion 
gene have higher PKA activity like in FLC patients. These engineered hepatocytes formed 
subcutaneous tumors at faster rate in vivo and significantly promoted ductular metaplasia tumors.  
 
Conclusion: DNAJB1-PRKACA fusion gene expression alone is sufficient to perturb cell 
growth and differentiation in different cellular contexts. In vivo modeling with engineered 
murine hepatocytes recapitulates certain prominent aspects of FLC pathological features, 
confirming its proposed role as a driver oncogene for FLC. Our Drosophila FLC model is ready 
as a medium throughput platform for FLC therapeutic screens.  
 
